Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study

Abstract Objective Metformin is the standard first-line drug for patients with Type 2 diabetes (T2DM). However, the optimal second-line oral anti-diabetic agent (ADA) remains unclear. We investigated the cardiovascular risk of various ADAs used as add-on medication to metformin in T2DM patients from...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Cheng-Wei Chan, Chu-Leng Yu, Jiunn-Cherng Lin, Yu-Cheng Hsieh, Che-Chen Lin, Chen-Ying Hung, Cheng-Hung Li, Ying-Chieh Liao, Chu-Pin Lo, Jin-Long Huang, Ching-Heng Lin, Tsu-Juey Wu
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMC 2018-01-01
Sarja:Cardiovascular Diabetology
Aiheet:
Anti-diabetic agent
Cardiovascular risk
Metformin
Type 2 diabetes
Linkit:http://link.springer.com/article/10.1186/s12933-018-0663-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia